Please provide your email address to receive an email when new articles are posted on . Seizure freedom was observed by 12 months and continued past 48 months of the open-label extension. Long-term ...

About 60-70% of focal epilepsy patients achieve seizure control with first-line antiseizure medications (ASMs). Lamotrigine and levetiracetam demonstrate high efficacy and tolerability for seizure ...

Epilepsy is a common neurological disorder that affects millions of people worldwide. Characterized primarily by seizures, epilepsy can present in a variety of ways depending on the individual and the ...

“It’s all about the brain,” said Jennifer DeWolfe, D.O., professor in the UAB Department of Neurology. “Seizure manifestations are stereotyped, so the same symptoms occur with each seizure that ...

Please provide your email address to receive an email when new articles are posted on . Monthly seizure frequency percentage reduction was 68.73% for the entire study cohort. For those followed up in ...

Longitudinal data suggested that treatment-resistant focal epilepsy may improve over time. Nearly 70% had reduced seizure frequency and some patients achieved seizure freedom. Improvement was not ...

About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly to available therapies. Yet they too may eventually see improvement, if not ...

Epilepsy is one of the most common neurological disorders, affecting 3.4 million Americans or 1 in 26 over a lifetime. The hallmark of epilepsy is seizures caused by abnormal bursts of electrical ...

Loss of consciousness can pose real dangers for people with seizure disorders. And while not all seizures cause loss of consciousness, Yale researchers have now discovered how one common type of ...

Loss of consciousness can pose real dangers for people with seizure disorders. And while not all seizures cause loss of consciousness, Yale researchers have now discovered how one common type of ...

Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well tolerated Patients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% ...

A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading. The study enrolled 30 ...